

*Agenda:* Discussion of Institute extramural research programs, health services research, and other program and peer review issues relevant to Council activities.

*Closed:* June 1, 8 a.m. to 10:30 a.m.

*Agenda:* To review and evaluate grant applications.

The following review committee meetings will be totally closed.

*Name of Committee:* Neuroscience and Behavior Subcommittee of the Alcohol Biomedical Research Review Committee.

*Dates of Meeting:* June 5–7, 1995.

*Time:* 9 a.m. to adjournment.

*Place of Meeting:* Hyatt Regency Bethesda, One Bethesda Metro Center, Bethesda, MD 20814.

*Contact Person:* Antonio Noronha, Ph.D., Scientific Review Administrator, 6000 Executive Blvd, Suite 409, Bethesda, MD 20892–7003, 301–443–9419.

*Agenda:* To review and evaluate grant applications.

*Name of Committee:* Clinical and Treatment Subcommittee of the Alcohol Psychosocial Research Review Committee.

*Dates of Meeting:* June 8–9, 1995.

*Time:* 8:30 a.m. to adjournment.

*Place of Meeting:* Hyatt Regency Bethesda, One Bethesda Metro Center, Bethesda, MD 20814.

*Contact Person:* Elsie D. Taylor, Scientific Review Administrator, 6000 Executive Blvd, Suite 409, Bethesda, MD 20892–7003, 301–443–9787.

*Agenda:* To review and evaluate grant applications.

*Name of Committee:* Epidemiology and Prevention Subcommittee of the Alcohol Psychosocial Research Review Committee.

*Dates of Meeting:* June 8–9, 1995.

*Time:* 8:30 a.m. to adjournment.

*Place of Meeting:* Holiday Inn, 480 King Street, Alexandria, VA.

*Contact Person:* Thomas D. Sevy, M.S.W., Scientific Review Administrator, 6000 Executive Blvd, Suite 409, Bethesda, MD 20892–7003, 301–443–6106.

*Agenda:* To review and evaluate grant applications.

*Name of Committee:* Biochemistry, Physiology, and Medicine Subcommittee of the Alcohol Biomedical Research Review Committee.

*Dates of Meeting:* June 15–17, 1995.

*Place of Meeting:* Double Tree Hotel, Denver, CO.

*Time:* 9 a.m. to adjournment.

*Contact Person:* Ronald Suddendorf, Ph.D., Scientific Review Administrator, 6000 Executive Blvd, Suite 409, Bethesda, MD 20892–7003, 301–443–2932.

*Agenda:* To review and evaluate grant applications.

(Catalog of Federal Domestic Assistance Program No. 93.271, Alcohol Research Career Development Awards for Scientists and Clinicians; 93.272, Alcohol National Research Service Awards for Research Training; 93.273, Alcohol Research Programs; 93.281, Scientist Development Award, Research Scientist Development Award, Scientist Development Award for Clinicians, and Research Scientist Award; 93.891, Alcohol Research Center Grants; National Institutes of Health).

Dated: May 3, 1995.

**Susan K. Feldman,**

*Committee Management Officer, NIH.*

[FR Doc. 95–11421 Filed 5–9–95; 8:45 am]

BILLING CODE 4140–01–M

### **National Institute of Arthritis and Musculoskeletal and Skin Disease; Notice of Meeting of the National Arthritis and Musculoskeletal and Skin Diseases Advisory Council**

Pursuant to Public Law 92–463, notice is hereby given of a meeting of the National Arthritis and Musculoskeletal and Skin Diseases Advisory Council to provide advice to the National Institute of Arthritis and Musculoskeletal and Skin Diseases on June 1 and 2, 1995, Conference Room 6, Building 31, National Institutes of Health, Bethesda, Maryland.

The meeting will be open to the public June 1 from 8:30 a.m. to 9 a.m. to discuss administrative details relating to Council business and special reports. Attendance by the public will be limited to space available.

The meeting of the Advisory Council will be closed to the public on June 1 from 9 a.m. to approximately 5 p.m. and if necessary the closed portion will continue on June 2 from 8:30 a.m. to adjournment in accordance with provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. and section 10(d) of Public Law 92–463, for the review, discussion and evaluation of individual grant applications. These deliberations could reveal confidential trade secrets or commercial property, such as patentable materials, and personal information concerning individuals associated with the applications, disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should contact Dr. Tommy Broadwater, Executive Secretary, National Arthritis and Musculoskeletal and Skin Diseases Advisory Council, NIAMS, Natcher Building, Room 5AS–13, Bethesda, Maryland 20892, (301) 594–2463.

A summary of the meeting and roster of the members may be obtained from the Extramural Programs Office, NIAMS, Natcher Bldg., Rm. 5AS–13, National Institutes of Health, Bethesda, Maryland 20892, (301) 594–2463.

(Catalog of Federal Domestic Assistance Program No. 93.846, Arthritis, Bone and Skin Diseases, National Institutes of Health)

Dated: May 3, 1995.

**Susan K. Feldman,**

*NIH Committee Management Officer.*

[FR Doc. 95–11419 Filed 5–9–95; 8:45 am]

BILLING CODE 4140–01–M

### **National Heart, Lung, and Blood Institute; Notice of Meeting**

Notice is hereby given of the meeting of the National Heart Attack Alert Program Coordinating Committee, sponsored by the National Heart, Lung, and Blood Institute on June 13, 1995, from 8:30 a.m. to 3:15 p.m., at the Bethesda Holiday Inn Hotel, 8120 Wisconsin Avenue, Bethesda, Maryland 20814, (301) 652–2000.

The entire meeting is open to the public. The Coordinating Committee is meeting to discuss the progress of the National Heart Attack Alert Program with its participating organizations. Attendance by the public will be limited to space available.

For the detailed program information, agenda, list of participants, and meeting summary, contact: Ms. Mary McDonald Hand, Coordinator, National Heart Attack Alert Program, Office of Prevention, Education and Control, National Heart, Lung, and Blood Institute, National Institutes of Health, 31 Center Drive MSC 2480, Bethesda, Maryland 20892–2480, (301) 496–1051.

Dated: May 3, 1995.

**Claude Lenfant,**

*Director, NHLBI.*

[FR Doc. 95–11425 Filed 5–9–95; 8:45 am]

BILLING CODE 4140–01–P

### **National Institute of Mental Health; Notice of Closed Meetings**

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings of the National Institute of Mental Health Special Emphasis Panel:

#### **Agenda/Purpose**

To review and evaluate grant applications.

*Committee Name:* National Institute of Mental Health Special Emphasis Panel.

*Date:* June 5, 1995.

*Time:* 2 p.m.

*Place:* Parklawn Building, Room 9C–26, 5600 Fishers Lane, Rockville, MD 20857.

*Contact Person:* Phyllis D. Artis, Grant Technical Assistant, Parklawn Building, Room 9C–26, 5600 Fishers Lane, Rockville, MD 20857, Telephone: 301, 443–6470.

*Committee Name:* National Institute of Mental Health Special Emphasis Panel.

*Date:* June 6, 1995.

*Time:* 12:30 p.m.

*Place:* Parklawn Building, Room 9C–26, 5600 Fishers Lane, Rockville, MD 20857.

Contact Person: Phyllis D. Artis, Grant Technical Assistant, Parklawn Building, Room 9C-26, 5600 Fishers Lane, Rockville, MD 20857, Telephone: 301, 443-6470.

The meetings will be closed in accordance with the provisions set forth in sec. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Program Numbers 93.126, Small Business Innovation Research; 93.176, ADAMHA Small Instrumentation Program Grants; 93.242, Mental Health Research Grants; 93.281, Mental Research Scientist Development Award and Research Scientist Development Award for Clinicians; 93.282, Mental Health Research Service Awards for Research Training; and 93.921, ADAMHA Science Education Partnership Award.)

Dated: May 3, 1995.

**Susan K. Feldman,**

*Committee Management Officer, NIH.*

[FR Doc. 95-11420 Filed 5-9-95; 8:45 am]

BILLING CODE 4140-01-M

### **Prospective Grant of Exclusive License: Oncoimmunins**

**AGENCY:** National Institutes of Health, Public Health Service, DHHS.

**ACTION:** Notice.

**SUMMARY:** This notice in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i) that the National Institutes of Health and Human Services, is contemplating the grant of an exclusive world-wide license to practice the inventions embodied in a U.S. Patent 5,364,619 and U.S. Patent Applications; USSN 07/764,695 and USSN 08/218,023 and corresponding foreign patent applications each entitled, "Oncoimmunins" to Oncoimmunin, Inc. of Kensington, Maryland. The patent rights in these inventions have been assigned to the United States of America.

The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless within sixty (60) days from the date of this published notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

Tumor-infiltrating lymphocytes (TILs) have shown in vivo antitumor efficacy in both animal and human studies. Functions thought necessary for antitumor activity include cytotoxicity, homing, and proliferation at tumor sites. T-cell mitogens of tumor origin have been suggested to be responsible, in part, for the local stimulation of T-lymphocytes around tumors. Two tumor-derived, soluble proteins named Oncoimmunin-L and Oncoimmunin-M have been isolated and partially characterized. Oncoimmunin-L is a T-cell mitogen and Oncoimmunin-M is a myeloid differentiation inducing agent. The partial characterization of these two factors has shown that they are similar to human leukocyte elastase inhibitor and human lactate dehydrogenase M, respectively. As cells of both lymphoid and myeloid origin are known to play roles in immune defense, factors which can modulate their number and/or function may be useful in the diagnosis and treatment of cancer. Since these factors are derived from tumors, their appearance in blood may signal the presence of tumor or of metastatic disease. The in vivo bioactivities of these factors suggests their utility as therapeutic agents for cancer and infectious diseases.

**ADDRESSES:** Requests for copies of the patent applications, inquiries, comments and other materials relating to the contemplated licenses should be directed to: Raphe Kantor, Ph.D., Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804. Telephone: (301) 496-7735 ext. 247; Facsimile: (301) 402-0220. A signed Confidentiality Agreement will be required to receive copies of the patent applications. Applications for a license in any field of use filed in response to this notice will be treated as objections to the grant of the contemplated licenses. Only written comments and/or applications for a license which are received by NIH on or before July 10, 1995 will be considered.

Dated: April 24, 1995.

**Maria C. Freire,**

*Director, Office of Technology Transfer.*

[FR Doc. 95-11423 Filed 5-9-95; 8:45 am]

BILLING CODE 4140-01-P

### **Prospective Grant of Exclusive License: Neuro-Derived Fetal Cell Lines for Transplantation Therapy**

**AGENCY:** National Institutes of Health, Public Health Service, DHHS.

**ACTION:** Notice.

**SUMMARY:** This is notice in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of an exclusive world-wide license to practice the inventions embodied in U.S. Patent 4,707,448, entitled "Immortal Line of Human Fetal Glial Cells," U.S. Patent Application SN 08/046,527 entitled "Use of Neuro-Derived Fetal Cell Line for Transplantation Therapy" and corresponding foreign patent applications to Pro-Virus, Inc. of Rockville, Maryland. The patent rights in these inventions have been assigned to the United States of America.

The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless within 60 days from the date of this published notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

The patent discloses a novel immortalized fetal glial cell line, designated SVG. The pending patent application discloses the methods of using such cell lines or genetically modified clones thereof for therapeutic purposes to treat various neurological diseases and disorders via transplantation of the cell lines into the patient. Cell lines, such as SVG, have the advantage of being a continually renewable resource and relatively homogenous. Additionally, such cell lines eliminate the significant safety concerns associated with primary human fetal tissue transplants that may harbor opportunistic disease-causing agents and may be subjected to a battery of tests to ensure their safety and efficacy before being used in transplantation.

**ADDRESSES:** Requests for copies of the patent and the patent applications, inquiries, comments and other materials relating to the contemplated licenses should be directed to: Mr. Arthur J. Cohn, Esq., Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20892-3804. Telephone: (301) 496-7735 ext 284; Facsimile: (301) 402-0220. A signed Confidentiality Agreement will be required to receive copies of the patent applications. Applications for a license in the field of use filed in response to this notice will be treated as objections to the grant of the contemplated